WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) will meet with institutional investors at healthcare conferences in London and Florida during November and December 2026, as the clinical-stage pharmaceutical company advances development of an experimental treatment for pulmonary arterial hypertension.
The company is developing IKT-001, a once-daily oral antiproliferative drug candidate for pulmonary arterial hypertension, or PAH, a disease characterized by elevated blood pressure in the arteries supplying the lungs.
Inhibikase Chief Executive Officer Mark Iwicki is scheduled to participate in a fireside discussion with Jefferies Research representative Dennis Ding at the Jefferies Global Healthcare Conference in London on November 16 at 3 p.m. Greenwich Mean Time.
The conference runs November 16-19, with Inhibikase management scheduled to hold individual investor meetings on November 16 and 17.
The company will also participate in the ninth annual Evercore Healthcare Conference in Coral Gables, Florida, running November 30 through December 2.
Inhibikase management plans to conduct one-on-one investor meetings at the Evercore event on December 1.
Investors seeking meetings at either conference should contact their respective Jefferies or Evercore representatives.
The appearances will provide Inhibikase opportunities to engage with investors as it pursues clinical development of IKT-001, its investigational treatment for PAH.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.